Next Article in Journal
Bioelectrical Impedance Phase Angle as a Prognostic Indicator of Survival in Head-and-Neck Cancer
Previous Article in Journal
Progression Pattern and Adverse Events with Bevacizumab in Glioblastoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 23
Issue 5
10.3747/co.23.2827
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Combined Sorafenib and Yttrium-90 Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma

by
A. Salman
1,
E. Simoneau
1,
M. Hassanain
2,3,
P. Chaudhury
1,2,
L.M. Boucher
4,
D. Valenti
4,
T. Cabrera
4,
C. Nudo
5 and
P. Metrakos
1,2,*
1
Department of Surgery and Pathology, McGill University Health Centre, 1001 Decarie Boulevard, E02.6218, Montreal, Quebec H4A 3J1, Canada
2
McGill Univ, Dept Oncol, Montreal, PQ, Canada
3
King Saud Univ, Dept Surg, Riyadh, Saudi Arabia
4
McGill Univ, Dept Radiol, Div Intervent Radiol, Montreal, PQ, Canada
5
McGill Univ, Dept Med, Div Hepatol, Montreal, PQ, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(5), 472-480; https://doi.org/10.3747/co.23.2827
Submission received: 2 July 2016 / Revised: 4 August 2016 / Accepted: 7 September 2016 / Published: 1 October 2016

Abstract

Background and Aims: In this pilot study, we assessed the safety and tolerability of combining sorafenib with 90Y radioembolization for the treatment of unresectable hepatocellular carcinoma (HCC). Methods: The study, conducted prospectively during 2009–2012, included eligible patients with unresectable HCC and a life expectancy of at least 12 weeks. Each patient received sorafenib (400 mg twice daily) for 6–8 weeks before 90Y treatment. Safety and tolerability were assessed. Results: Of the 40 patients enrolled, 29 completed treatment (combined therapy). In the initial cohort, the most common cause of HCC was hepatitis C (32.5%), and most patients were staged Child A (82.5%). The 29 patients who completed the study had similar baseline characteristics. Grades 1 and 2 toxicities accounted for 77.8% of all adverse events reported. The most common toxicities reported were fatigue (19.0%), alteration in liver function (7.9%), and diarrhea (6.3%). There were 12 grade 3 and 2 grade 4 toxicity events reported. One patient died of liver failure within 30 days after treatment. During the study, the sorafenib dose was reduced in 6 patients (20.7%), and sorafenib had to be interrupted in 4 patients (13.8%) and discontinued in 4 patients (13.8%). The disease control rate was 72.4% per the modified Response Evaluation Criteria in Solid Tumors, and tumour necrosis was observed in 82.8% of patients. Overall survival in patients undergoing combined therapy was 12.4 months. Conclusions: Preliminary results demonstrate the safety and tolerability of combining 90Y radioembolization and sorafenib for advanced HCC. A larger prospective study is needed to determine the extent of the survival benefit.
Keywords: hepatocellular carcinoma; radioembolization; sorafenib; unresectability hepatocellular carcinoma; radioembolization; sorafenib; unresectability

Share and Cite

MDPI and ACS Style

Salman, A.; Simoneau, E.; Hassanain, M.; Chaudhury, P.; Boucher, L.M.; Valenti, D.; Cabrera, T.; Nudo, C.; Metrakos, P. Combined Sorafenib and Yttrium-90 Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma. Curr. Oncol. 2016, 23, 472-480. https://doi.org/10.3747/co.23.2827

AMA Style

Salman A, Simoneau E, Hassanain M, Chaudhury P, Boucher LM, Valenti D, Cabrera T, Nudo C, Metrakos P. Combined Sorafenib and Yttrium-90 Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma. Current Oncology. 2016; 23(5):472-480. https://doi.org/10.3747/co.23.2827

Chicago/Turabian Style

Salman, A., E. Simoneau, M. Hassanain, P. Chaudhury, L.M. Boucher, D. Valenti, T. Cabrera, C. Nudo, and P. Metrakos. 2016. "Combined Sorafenib and Yttrium-90 Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma" Current Oncology 23, no. 5: 472-480. https://doi.org/10.3747/co.23.2827

APA Style

Salman, A., Simoneau, E., Hassanain, M., Chaudhury, P., Boucher, L. M., Valenti, D., Cabrera, T., Nudo, C., & Metrakos, P. (2016). Combined Sorafenib and Yttrium-90 Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma. Current Oncology, 23(5), 472-480. https://doi.org/10.3747/co.23.2827

Article Metrics

Back to TopTop